Conclusion The plasminogen ability is lower in women with PCOS.
结论PCOS患者的血纤溶能力较正常对照者有所下降。
We studied the mechanism of plasma and tissue kallikrein in activating plasminogen.
作者研究了血浆和组织激肽释放酶激活纤溶酶原的机制。
Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
We measured the plasminogen (PLG) content and plasmin (pl) activity in 54 leukemic patients.
对54例白血病患者进行血浆纤溶酶原(plg)及纤溶酶(PL)活性测定。
Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.
尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。
HMGB1 plays roles in activation of plasminogen and matrix metalloproteases, reorganization of cytoskeleton.
HMGB1与纤维蛋白酶原、基质金属蛋白酶的活化、细胞骨架重组等有关。
This method provided a new, fast and efficient method for large-scale purification of plasminogen for clinic use.
为规模化快速纯化临床用高纯度纤溶酶原提供了新方法。
NIHSS scores were determined before tissue plasminogen activator bolus and at 60 and 120 minutes in both data sets.
在两个试验中，在组织纤维蛋白溶酶原激活剂使用前，都先用NIHSS评分。
Plasminogen activator inhibitor-1 (PAI-1) is a single strand glycoprotein, which can inhibit plasminogen activation.
纤溶酶原激活物抑制剂1 (PAI - 1)是一种单链糖蛋白，起抑制纤溶活性的作用。
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
Objective to observe the effect of recombinant tissue plasminogen activator in the treatment of acute myocardial infarction.
目的观察应用重组组织型纤溶酶原激活剂溶栓治疗急性心肌梗死的效果。
Objective: to study the risk factor of Triglyceride and Plasminogen Activity on abnormal in patients with Cerbral Infarction.
前言：目的：探讨脑梗塞患者血高甘油三酯与纤溶系统异常的危险因素。
ObjectivesTo study the change of plasminogen activation system in different behavior type patients with coronary heart disease.
目的研究不同行为类型冠心病患者之间纤溶激活系统的变化。
Objective: To identify the significance of urokinase-type plasminogen activator expression in patients with epithelial ovarian carcinoma.
目的：探讨尿激酶型纤溶酶原激活因子的蛋白表达与上皮性卵巢癌生物学行为的关系。
Objectives: To study the difference of Plasminogen Activation System in patients with coronary heart disease by different behavior types.
前言：目的：研究不同行为类型冠心病患者之间纤溶激活系统的变化。
Objective To study the changes of the endothelial tissue plasminogen activator reserve capacity in patients with acute coronary syndromes.
目的探讨急性冠状动脉综合征患者内皮组织纤溶酶原激活剂储备功能的变化规律。
Reciprocal activation of prourokinase and plasminogen is an important mechanism in the initiation and propagation of local fibrinolytic activity.
纤溶酶原和尿激酶前体的相互活化作用在纤溶的开始和加速上发挥着重要的作用。
Objective To investigate the relationship between the plasminogen activator inhibitor 1(PAI 1) promotor region gene polymorphism and cerebral stroke.
目的探讨纤溶酶原激活物抑制物-1（PAI- 1）启动子区基因多态性与脑卒中的关系。
Objective to study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).
目的研究纤溶酶原激活物抑制剂(PAI1)与肝细胞癌(HCC)生物学特性的关系。
Objective To investigate the effect of simvastatin, ticlopidin and aspirin on the plasma plasminogen activitor inhibitor-l(PAI-1) contents in CHD patients.
目的研究辛伐他汀、抵克立得、阿司匹林对冠心病（CHD）患者血浆PAI-1含量的影响。
The screening of human tissue plasminogen activator recombinant plasmid showed that the two methods can recognize the positive colones quickly and correctly.
测序结果表明这两种方法能快速，准确地筛选出阳性克隆。
Method Plasminogen activator inhibitor-1(PAI-1) in 33 cases of diabetic nephropathy and 30 healthy controls were detected, and the test results were observed.
方法：检测33例糖尿病肾病患者及30例健康体检对照组血浆纤溶酶原激活物抑制物-1（PAI-1），观察检测结果。
AIM: To observe the effect of extract of Ginkgo biloba leaves on plasminogen activator inhibitor 1(PAI-1)and thromboxane B2(TXB-2)in type 2 diabetes mellitus(DM).
目的：观察银杏叶提取物对2型糖尿病病人纤溶酶原激活物抑制物1（PAI 1）及凝血烷B2（TXB 2 ）的影响。
Plasminogen activator inhibitor-1 (PAI-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.
纤溶酶原激活物抑制物1 (PAI - 1)是血浆纤维蛋白溶解系统的重要组成物之一，对维持血浆纤溶系统的稳定起重要作用。
The thrombolytic effect was compared between urokinase (UK) and human tissue plasminogen activator (t-PA) in rabbits with experimental iliofemoral artery thrombus.
本文用尿激酶(UK)和人体组织型纤溶酶原激活剂(t - PA)进行了兔髂股动脉血栓实验性溶解的对照研究。
This was accompanied by severe disruption of the blood-brain barrier and an increased rate of intracerebral hemorrhages after tissue plasminogen activator treatment.
这一现象伴随血脑屏障的严重破坏和组织型纤维蛋白溶酶原激活剂治疗后的脑出血率增加。
Objective: to investigate the clinical effectiveness of prolonged low-dose urine plasminogen activator (u-PA) therapy in patients with unstable angina pectoris (UAP).
目的：观察小剂量长疗程尿纤溶酶原激活物(u - PA)治疗不稳定型心绞痛(uap)的临床疗效。
The enzyme showed strong fibrinolytic activity on fibrin and esterase activity in BAEE. It shows two effects, both acting on fibrin directly and activating plasminogen.
该酶具有强烈的纤溶活力和水解BAEE的活力，能直接作用纤维蛋白和间接激活纤溶酶原。
Objective To investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(PAI 1) by human pleural mesothelial cells(HPMC).
目的研究前炎症细胞因子对人胸膜间皮细胞（HPMC）释放纤溶酶原激活物抑制剂（PAI1）的诱导效应。
Objective To investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(PAI 1) by human pleural mesothelial cells(HPMC).
目的研究前炎症细胞因子对人胸膜间皮细胞（HPMC）释放纤溶酶原激活物抑制剂（PAI1）的诱导效应。
应用推荐